Clinical Trial Update: Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the efficacy and safety of fingolimod (Gilenya) in relapsing-remitting multiple sclerosis, with results from the completed study poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2011-03-16